Cargando…

Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients

Detalles Bibliográficos
Autores principales:	Ovcar, Eugen, Patyna, Sammy, Kohmer, Niko, Heckel-Kratz, Elisabeth, Ciesek, Sandra, Rabenau, Holger F, Hauser, Ingeborg A, de Groot, Kirsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664578/ https://www.ncbi.nlm.nih.gov/pubmed/36381372 http://dx.doi.org/10.1093/ckj/sfac211

Ejemplares similares

Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients
por: Ovcar, Eugen, et al.
Publicado: (2023)

Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
por: Patyna, Sammy, et al.
Publicado: (2022)

Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies
por: Kohmer, Niko, et al.
Publicado: (2021)

Clinical performance of different SARS‐CoV‐2 IgG antibody tests
por: Kohmer, Niko, et al.
Publicado: (2020)

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays
por: Kohmer, Niko, et al.
Publicado: (2020)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
por: Wilhelm, Alexander, et al.
Publicado: (2022)

Comparative analysis of point-of-care, high-throughput and laboratory-developed SARS-CoV-2 nucleic acid amplification tests (NATs)
por: Kohmer, Niko, et al.
Publicado: (2021)

Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study
por: Koehm, Michaela, et al.
Publicado: (2023)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

Suitability of Different Diagnostic Platforms for Virological Testing of Blood Samples from Cornea Donors
por: Kohmer, Niko, et al.
Publicado: (2022)

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
por: Doria-Rose, Nicole A., et al.
Publicado: (2021)

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
por: Muik, Alexander, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination
por: Habermann, Elisa, et al.
Publicado: (2022)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater
por: Wilhelm, Alexander, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Reply to Fabbris et al. A Viable Alternative. Comment on “Kohmer et al. Self-Collected Samples to Detect SARS-CoV-2: Direct Comparison of Saliva, Tongue Swab, Nasal Swab, Chewed Cotton Pads and Gargle Lavage. J. Clin. Med. 2021, 10, 5751”
por: Hoehl, Sebastian, et al.
Publicado: (2022)

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
por: Routhu, Nanda Kishore, et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Adrenal insufficiency in a haemodialysis patient
por: Suzuki, Ryuji, et al.
Publicado: (2010)

Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France
por: Tamandjou, Cynthia, et al.
Publicado: (2023)

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2
por: Swart, Maarten, et al.
Publicado: (2023)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2022)

Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
por: Amir, Ofra, et al.
Publicado: (2023)

The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro
por: Kohmer, Niko, et al.
Publicado: (2021)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients
por: Platen, Louise, et al.
Publicado: (2023)

EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance
por: Maschio, M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nr4p53d1qffbeu64mm5qs9ukc2